Modulation of cardiac metabolism during myocardial ischemia

Current Pharmaceutical Design

Volumn 14, Issue 25, 2008, Pages 2563-2571

  Chagas, Antonio C P ^a   Dourado, Paulo M M ^a   Gonçalves Galvão, Tatiana de Fátima ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Cardiac ischemia; Ischemic preconditioning; Metabolic modulation; Myocardial infarct; Reperfusion

Indexed keywords

AMLODIPINE; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARDIAC AGENT; ETOMOXIR; NIFEDIPINE; PERHEXILINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PLACEBO; PROPRANOLOL; RANOLAZINE; TRIMETAZIDINE;

ADJUVANT THERAPY; ANGINA PECTORIS; CLINICAL FEATURE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CORONARY ARTERY DISEASE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MONITORING; DRUG SAFETY; EXERCISE TEST; FATTY ACID OXIDATION; GLUCOSE METABOLISM; GLUCOSE UTILIZATION; HEART ARRHYTHMIA; HEART FAILURE; HEART FUNCTION; HEART INFARCTION PREVENTION; HEART MUSCLE BLOOD FLOW; HEART MUSCLE CONTRACTILITY; HEART MUSCLE ISCHEMIA; HEART MUSCLE METABOLISM; HEART MUSCLE OXYGEN CONSUMPTION; HEART MUSCLE REPERFUSION; HEART MUSCLE REVASCULARIZATION; HEART PROTECTION; HUMAN; HYPOXIA; ISCHEMIC PRECONDITIONING; LIVER TOXICITY; MONOTHERAPY; MYOCARDIAL HIBERNATION; NEUROTOXICITY; NONHUMAN; PATHOPHYSIOLOGY; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; REVIEW;

ANIMALS; CARDIOVASCULAR AGENTS; HUMANS; ISCHEMIC PRECONDITIONING, MYOCARDIAL; MYOCARDIAL ISCHEMIA; MYOCARDIUM;

EID: 57349105703     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161208786071236     Document Type: Review

References (119)

1. Yellon DM, Downey JM. Preconditioning the myocardium: from cellular physiology to clinical Cardiology. Physiol Rev 2003; 83: 1113-51.
2. Murray CJ, Lopez AD. Alternate projections of mortality and disability by cause 1990-2220: global burden of disease study. Lancet 1997; 349: 1498-504.
3. Neubauer S. The failing heart - an engine out of fuel. N Engl J Med 2007; 356: 1140-51.
4. Bessman SP, Geiger PJ. Transport of energy in muscle: the phosphorylcreatine shuttle. Science 1981; 211: 448-52.
5. Ingwall JS. ATP and the heart. Norwell, MA: Kluwer Academic 2002.
6. Wallimann T, Wyss M, Brdiczka D, Nicolay K, Eppenberger HM. Intracellular compartmentation, structure and function of creatine kinase isoenzymes in tissues with high and fluctuating energy demands: the 'phosphocreatine circuit' for cellular energy homeostasis. Biochem J 1992; 281: 21-40.
7. Guimbal C, Kilimann MWA. A Na(+)- dependent creatine transporter in rabbit brain, muscle, heart, and kidney: cDNA cloning and functional expression. J Biol Chem 1993; 268: 8418-21.
8. Wyss M, Wallimann T. Creatine metabolism and the consequences of creatine depletion in muscle. Mol Cell Biochem 1994; 133-134: 51-66.
9. Lee L, Horowitz J, Frenneaux M. Metabolic manipulation in ischaemic heart disease, a novel approach to treatment. Eur Heart J 2004; 25: 634-41.
10. Stanley WC, Lopaschuk GD, Hall JL, McCormack JG. Regulation of myocardial carbohydrate metabolism under normal and ischaemic conditions. Potential for pharmacological interventions. Cardiovasc Res 1997; 33: 243-57.
11. Gertz EW, Wisneski JA, Stanley WC, Neese RA. Myocardial substrate utilization during exercise in humans. Dual carbonlabeled carbohydrate isotope experiments. J Clin Invest 1988; 82: 2017-25.
12. Liedtke AJ. Alterations of carbohydrate and lipid metabolism in the acutely ischemic heart. Prog Cardiovasc Dis 1981; 23: 321-36.
13. Zhou L, Salem JE, Saidel GM, Stanley WC, Cabrera ME. Mechanistic model of cardiac energy metabolism predicts localization of glycolysis to cytosolic subdomain during ischemia. Am J Physiol Heart Circ Physiol 2005; 288: H2400-11.
14. Fukumoto GH, Lamp ST, Motter C, Bridge JH, Garfinkel A, Goldhaber JI. Metabolic inhibition alters subcellular calcium release patterns in rat ventricular myocytes: implications for defective excitation-contraction coupling during cardiac ischemia and failure. Circ Res 2005; 96: 551-7.
15. McNulty PH, Jagasia D, Cline GW, Ng CK, Whiting JM, Garg P, et al. Persistent changes in myocardial glucose metabolism in vivo during reperfusion of a limited-duration coronary occlusion. Circulation 2000; 101: 917-22.
16. Tamm C, Benzi R, Papageorgiou I, Tardy I, Lerch R. Substrate competition in postischemic myocardium. Effect of substrate availability during reperfusion on metabolic and contractile recovery in isolated rat hearts. Circ Res 1994; 75: 1103-12.
17. Stanley WC. Cardiac energetics during ischaemia and the rationale for metabolic interventions. Coron Artery Dis 2001; 12 (Suppl 1): S3-7.
18. Taegtmeyer H, Roberts AF, Raine AE. Energy metabolism in reperfused heart muscle: metabolic correlates to return of function. J Am Coll Cardiol 1985; 6: 864-70.
19. Depre C, Vanoverschelde JL, Taegtmeyer H. Glucose for the heart. Circulation 1999; 99: 578-88.
20. Lopaschuk GD, Wambolt RB, Barr RL. An imbalance between glycolysis and glucose oxidation is a possible explanation for the detrimental effects of high levels of fatty acids during aerobic reperfusion of ischemic hearts. J Pharmacol Exp Ther 1993; 264: 135-44.
21. Heusch G. Hibernating myocardium. Physiol Rev 1998; 78: 1055-85.
22. Murnaghan MF. Effect of fatty acids on the ventricular arrhythmia threshold in the isolated heart of the rabbit. Br J Pharmacol 1981; 73: 909-15.
23. Kennedy JA, Kiosoglous AJ, Murphy GA, Pelle MA, Horowitz JD. Effect of perhexiline and oxfenicine on myocardial function and metabolism during low-flow ischemia/reperfusion in the isolated rat heart. J Cardiovasc Pharmacol 2000; 36: 794-801.
24. Jones SP, Lefer DJ. Myocardial reperfusion injury: insights gained from gene-targeted mice. News Physiol Sci 2000; 15: 303-8.
25. Rossoni G, Manfredi B, Colonna VD, Bernareggi M, Berti F. The nitroderivate of aspirin, NCX 4016, reduces infarct size caused by myocardial-reperfusion in the anesthetized rat. J Pharnacol Exp Ther 2001; 297: 380-7.
26. Mullane KM, Read N, Salmon JA, Moncada S. Role of leukocytes in acute myocardial infarction in anesthetized dogs: relationship to myocardial salvage by anti-inflammatory drugs. J Pharmacol Exp Ther 1984; 228: 510-22.
27. Frangogiannis NG, Mendoza LH, Lindsey ML, Ballantyne CM, Michael LH, Smith CW, et al. IL-10 is induced in the reperfused myocardium and may modulate the reaction to injury. J Immunol 2000; 165: 2798-808.
28. Roberts R, de Mello V, Sobel BE. Deleterious effects of methylprednisolone in patients with myocardial infarction. Circulation 1975; 53 (Suppl 1): 1204-8.
29. Hammerman H, Kloner RA, Hale S, Schoen FJ, Braunwald E. Dose-dependent effects of short-term methylprednisolone on myocardial infarct extent, scar formation, and ventricular function. Circulation 1983; 68: 446-52.
30. Black SC. In vivo models of myocardial ischemia and reperfusion injury. Application to drug discovery and evaluation. J Pharmacol Toxicol Methods 2000; 43: 153-67.
31. Selke FW. Vascular changes after cardiopulmonary bypass and ischemic cardiac arrest: roles of nitric oxide synthase and cyclooxygenase. Braz J Med Biol Res 1999; 32: 1345-52.
32. Attur MG, Patel RN, Patel PD, Abramson SB, Amin AR. Tetracycline up-regulates COX-2 expression and prostaglandin E2 production independent of its effects on nitric oxide. J Immunol 1999; 162: 3160-7.
33. Nogawa S, Forster C, Zhang F, Nagayama M, Ross ME, Interaction between inducible nitric oxide synthase and cyclooxygenase-2 after cerebral ischemia. Proc Natl Acad Sci USA 1998; 95: 10966-71.
34. Scheuren N, Jacobs M, Ertl G, Schorb W. Cyclooxygenase-2 in myocardium stimulation by angiotensina-II in cultured cardiac fibroblasts and role at acute myocardial infarction. J Mol Cell Cardiol 2002; 34: 29-37.
35. Saito T, Rodger IW, Hu F, Shennib H, Giaid A. Inhibition of cyclooxygenase-2 improves cardiac function in myocardial infarction. Biochem Biophys Res Commun 2000; 273: 772-5.
36. Shinmura K, Tang XL, Wang Y, Bolli R. Cyclooxygenase-2 mediates the cardioprotective effects of the late phase of ischemic preconditioning in conscious rabbits. Proc Natl Acad Sci USA 2000; 97: 10197-202.
37. Altman R, Luciardi HL, Muntaner J, Del Rio F, Berman SG, Lopez R, et al. Efficacy assessment of meloxicam, a preferencial cicloxigenase-2 inhibitor, in acute coronary sindromes without STsegment elevation. The nonsteroidal anti-inflamatory drugs in unstable angina treatment-2 (NUT-2) pilot study. Circulation 2002; 106: 191-5.
38. Hocherl K, Dreher F, Kurtz A, Bucher M. Cyclooxygenase-2 inhibiton attenuates lipopolysaccharide-induced cardiovascular failure. Hypertension 2002; 40: 947-53.
39. Pitt B, Pepine C, Willerson JT. Cyclooxygenase-2 inhibition and cardiovascular events. Circulation 2002; 106: 167-9.
40. Carnieto A. Inibição seletiva da ciclooxigenase-2 protege contra a lesão miocárdica em um modelo experimental de isquemia aguda. Doutorado Thesis. Faculdade de Medicina da USP. Departamento de Cardiopneumologia - São Paulo SP: Brazil 2003.
41. Neubauer S, Horn M, Naumann A, Tian R, Hu K, Laser M, et al. impairment of energy metabolism in intact residual myocardium of rat hearts with chronic myocardial infarction. J Clin Invest 1995; 95: 1092-100.
42. Maroko PR, Kjekshus JK, Sobel BE, Watanabe T, Covell JW, Ross J Jr, et al. Factors influencing infarct size following experimental coronary artery occlusions. Circulation 1971; 43: 67-82.
43. Maroko PR, Libby P, Sobel BE, Bloor CM, Sybers HD, Shell WE, et al. Effect of glucose-insulin-potassium infusion on myocardial infarction following experimental coronary artery occlusion. Circulation 1972; 45: 1160-75.
44. Maroko PR, Libby P, Bloor CM, Sobel BE, Braunwald E. Reduction by hyaluronidase of myocardial necrosis following coronary artery occlusion. Circulation 1972; 46: 430-7.
45. Jennings RB, Reimer KA. Factors involved in salvaging ischemic myocardium: effect of reperfusion of arterial blood. Circulation 1983; 68 (Suppl 1): I-25-36.
46. Chagas AC, Pillegi F, Lopes EA, Da Luz PL. Myocardial protection in the occlusion/reperfusion dog model: the role of ischemic necrosis vs reperfusion injury. Braz J Med Biol Res 1995; 28: 951-9.
47. Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation 1986; 74: 1124-36.
48. Schultz JJ, Rose E, Yao Z, Gross GJ. Evidence for involvement of opioid receptors in ischemic preconditioning in rat hearts. Am J Physiol 1995; 268: H2157-61.
49. Schott RJ, Rohmann S, Braun ER, Schaper W. Ischemic preconditioning reduces infarct size in swine myocardium. Circ Res 1990; 66: 1133-42.
50. Liu GS, Thornton J, Van Winkle DM, Stanley AW, Olsson RA, Downey JM. Protection against infarction afforded by preconditioning is mediated by A1 adenosine receptors in rabbit heart. Circulation 1991; 84: 350-6.
51. Gross GJ, Auchampach JA. Blockade of the ATP-sensitive potassium channels prevents myocardial preconditioning. Circ Res 1992; 70: 223-33.
52. Liu Y, Downey JM. Ischemic preconditioning protects against infarction in rat heart. Am J Physiol 1992; 263: H1107-12.
53. Liang BT, Gross GJ. Direct preconditioning of cardiac myocites via opioid receptors and KATP channels. Circ Res 1999; 84: 1396-1400.
54. Burns PG, Krukenkamp IB, Caldarone CA, Gaudette GR, Bukhari EA, Levitsky S. Does cardiopulmonary bypass alone elicit myoprotective preconditioning. Circulation 1995; 92: 447-51.
55. Tomai F, Crea F, Gaspardone A, Versaci F, De Paulis R, Penta de Peppo A, et al. Ischemic preconditioning during angioplasty is prevented by glibenclamide, a selective ATP-sensitive K+ channel blocker. Circulation 1994; 90: 700-5.
56. Cohen MV, Walsh RS, Goto M, Downey JM. Hypoxia preconditions rabbit myocardium via adenosine and catecholamine release. J Mol Cell Cardiol 1995; 27: 1527-34.
57. Vegh A, Szekeres L, Parratt JR. Transient ischaemia induced by rapid cardiac pacing results in myocardial preconditioning. Cardiovasc Res 1991; 25: 1051-3.
58. Koning MM, Gho BC, van Klaarwater E, Opstal RL, Duncker DJ, Verdouw PD. Rapid ventricular pacing produces myocardial protection by nonischemic activation of K-ATP channels. Circulation 1996; 93: 178-86.
59. Cumming DV, Heads RJ, Brand NJ, Yellon DM, Latchman DS. The ability of heat stress and metabolic preconditioning to protect primary rat cardiac myocites. Basic Res Cardiol 1996; 91: 79-85.
60. Ovize M, Kloner RA, Przyklenk K. Stretch preconditions canine myocardium. Am J Physiol 1994; 266: H137-46.
61. Gysembergh A, Margonari H, Loufoua J, Ovize A, André-Fouët X, Minaire Y, et al. Stretch-induced protection shares a common mechanism with ischemic preconditioning in rabbit heart. Am J Physiol 1998; 274: H955-64.
62. Yellon DM, Baxter GF, Garcia-Dorado D, Heusch G, Sumeray MS. Ischaemic preconditioning: present position and future directions. Cardiovasc Res 1998; 37: 21-33.
63. Przyklenk K, Kloner RA, Whittaker P. Synopsis of ischemic preconditioning: what have we learned since 1986? In Ref 4: 153-70.
64. Thornton JC, Liu GS, Downey JM. Pretreatment with pertussis toxin blocks protective effects of preconditioning: evidence for a G-ptotein mechanism. J Mol Cell Cardiol 1993; 25: 311-20.
65. Downey JM, Liu Y, Ytrehus K. Adenosine and the antiinfarct effects of preconditioning. In Ref. 4: 137-52.
66. Ytrehus K, Liu Y, Downey JM. Preconditioning protects the ischemic rabbit heart by protein Kinase C activation (abstract). FASEB J 1993; 7: A418.
67. Wolfe CL, Stevens RE, Vissern FLJ, Donnelly TJ. Loss of myocardial protection after preconditioning correlates with the time course of glycogen recovery within the preconditionated segment. Circulation 1993; 87: 881-92.
68. Cohen MV, Yang XM, Liu GS, Heusch G, Downey JM. Acetylcholine, Bradykinin, Opioids, and Phenylephrine, but not Adenosine, trigger preconditioning by generating free radicals and opening mitochondrial K-ATP Channels. Circ Res 2001; 89: 273-8.
69. Ferguson RJ, Cote P, Gauthier P, Bourassa MG. Changes in exercise coronary sinus blood flow with training in patients with angina pectoris. Circulation 1978; 58: 41-7.
70. Nolewajka AJ, Kostuk WL, Rechnitzer PA, Cunningham DA. Exercise and human collateralization: an angiographic and scintigraphic assessment. Circulation 1979; 60: 114-21.
71. Shizukuda YR, Mallet T, Lee SC, Downey HF. Hypoxic preconditioning of ischaemic canine myocardium. Cardiovasc Res 1992; 26: 534-42.
72. Mayfield KP, D'Alecy LG. Delta-1 opioid agonist acutely increases hypoxic tolerance. J Pharmacol Exp Ther 1994; 268: 683-8.
73. Mayfield KP, D'Alecy LG. Delta-1 opioid receptor dependence of acute hypoxic adaptation. J Pharmacol Exp Ther 1994; 268: 74-7.
74. Heberden W. Letter to Medical Transactions of the College of Physicians (London). In: Lewis,T. Pain in muscular ischemia. Arch Intern Med 1932; 49: 713.
75. MacAlpin RN, Kattus AA. Adaptation to exercise in angina pectoris: the electrocardiogram during treadmill walking and coronary angiographic findings. Circulation 1966; 33: 183-201.
76. Jaffe MD, Quinn NK. Warm-up phenomenon in angina pectoris. Lancet 1980; 2: 934-6.
77. Okazaki Y, Kodama K, Sato H, Kitakaze M, Hirayama A, Mishima M, et al. Attenuation of increased regional myocardial oxygen consumption during exercise as a major cause of warm-up phenomenon. J Am Col Cardiol 1993; 21: 1597-604.
78. Willians DO, Bass TA, Gerwitz H, Most AS. Adaptation to the stress of tachycardia in patients with coronary artery disesase: insight into the mechanism of the warm-up phenomenon. Circulation 1985; 71: 687-92.
79. Marber MS, Latchman DS, Walker M, Yellon DM. Cardiac stress protein elevation 24 hours after brief ischemia or heat stress is associated with resistance to myocardial infarction. Circulation 1993; 88: 1264-72.
80. Kuzuya T, Hoshida S, Yamashita N, Fuji H, Oe H, Hori M, et al. Delayed effects of sublethal ischemia on the acquisition of tolerance to ischemia. Circ Res 1993; 72: 1293-9.
81. Baxter GF, Marber MS, Patel VC, Yellon DM. A second window of protection 24 hours after ischemic preconditioning may be dependent upon adenosine receptor activation (abstract). Circulation 1993; 88 (Suppl I (Pt 2)): I-101A.
82. Patel HH, Hsu AK, Peart JN, Gross GJ. Sarcolemmal K-ATP channel triggers opioid-induced delayed cardioprotection in the rat. Circ Res 2002; 91: 186-8.
83. Li Y, Kloner RA. The cardioprotective effects of ischemic "preconditioning" are not mediated by adenosine receptors in rat hearts. Circulation 1993; 87: 1642-8.
84. Shiki K, Hearse DJ. Preconditioning of ischemic myocardium: reperfusion-induced arrhythmias. Am J Physiol 1987; 253: H1470-6.
85. Hagar JM, Hale SL, Kloner RA. Effect of preconditioning ischemia on reperfusion arrhythmias after coronary artery occlusion and reperfusion in the rat. Circ Res 1991; 68: 61-8.
86. Vegh A, Szekeres L, Parratt JR. Protective effects of preconditioning of the ischemic myocardium involves cyclooxygenase products. Cardiovasc Res 1990; 24: 1020-3.
87. Sokolova RI, Zhdanov VS. Hibernation and stunning as manifestations of ischemic dysfunction of the myocardium. Arkh Pathol 2002; 64: 50-54.
88. Wijns W, Vatner SF, Camici PG. Hibernating myocardium. N Engl J Med 1998; 339: 173-81.
89. Rahimtoola SH. A perspective on the three large multicenter randomized clinical trials of coronary bypass surgery for chronic stable angina. Circulation 1985; 72 (Suppl V): V-123-5.
90. Rahimtoola SH. The hibernating myocardium. Am Heart J 1989; 117: 211-21.
91. Stanley WC, Lopaschuk GD, Hall JL, McCormack JG. Regulation of myocardial carbohydrate metabolism under normal and ischemic conditions: potential for pharmacological interventions. Cardiovasc Res 1997; 33: 243-57
92. Wang P, Lloyd SG, Chatham JC. Impact of high glucose/high insulin and dichloroacetate treatment on carbohydrate oxidation and functional recovery after low-flow ischemia and reperfusion in the isolated perfused rat heart. Circulation 2005; 111: 2066-72.
93. Lee L, Horowitz J, Frenneaux M. Metabolic manipulation in ischaemic heart disease: a novel approach to treatment. Eur Heart J 2004; 25: 634-41.
94. Essop MF, Opie LH. Metabolic therapy for heart failure. Eur Heart J 2004; 25: 1765-8.
95. Wolff AA, Rotmensch HH, Stanley WC, Ferrari R. Metabolic approaches to the treatment of ischemic heart disease: the clinicians' perspective. Heart Fail Rev 2002; 7: 187-203.
96. Schmidt-Schweda S, Holubarsch C. First clinical trial with etomoxir in patients with chronic congestive heart failure. Clin Sci (Lond) 2000; 99: 27-35.
97. Napoli P, Taccardi AA, Barsotti A. Long term cardioprotective action of trimetazidine and potential effect on the inflammatory process in patients with ischaemic dilated cardiomyopathy. Heart 2005; 91: 161-5.
98. Siddiqui MA, Keam SJ. Ranolazine: a review of its use in chronic stable angina pectoris. Drugs 2006; 66: 693-710.
99. Lopaschuk GD, Barr R, Thomas PD, Dyck JRB. Beneficial effects of trimetazidine in ex vivo working ischemic hearts are due to a stimulation of glucose oxidation secondary to inhibition of longchain 3-ketoacyl coenzyme A thiolase. Circ Res 2003; 93; e33-7.
100. Detry JM, Sellier P, Pennaforte S, Cokkinos D, Dargie H, Mathes P. Trimetazidine: a new concept in the treatment of angina: comparison with propranolol in patients with stable angina. Trimetazidine European Multicenter Study Group. Br J Clin Pharmacol 1994; 3: 279-88.
101. Dalla-Volta S, Maraglino G, Della-Valentina P, Viena P, Desideri A. Comparison of trimetazidine with nifedipine in effort angina: a doubleblind, crossover study. Cardiovasc Drugs Ther 1990; 4: 853-9.
102. Manchanda SC, Krishnaswani S. Combination treatment with trimetazidine and diltiazem in stable angina pectoris. Heart 1997; 78: 353-7.
103. Szwed H, Sadowski Z, Elikowski W, Koronkiewicz A, Mamcarz A, Orszulak W, et al. Combination treatment in stable effort angina using trimetazidine and metoprolol: results of a randomized, double-blind, multicentre study (TRIMPOL II). Eur Heart J 2001; 22: 2267-74.
104. Kober G, Buck T, Sievert H, Vallbracht C. Myocardial protection during percutaneous transluminal coronary angioplasty: effects of Trimetazidine. Eur Heart J 1992; 13: 1109-15.
105. The EMIP-FR Group. Effect of 48 h IV trimetazidine on short and long-term outcomes of patients with acute myocardial infarction, with anwithout thrombolytic therapy. Eur Heart J 2000; 18: 1537-46.
106. Kantor PF, Lucien A, Kozak R, Lopaschuk GD. The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial longchain 3-ketoacyl coenzyme a thiolase. Circ Res 2000; 86: 580-8.
107. Levy S, Group of South of France Investigators. Combination therapy of trimetazidine with diltiazem in patients with coronary artery disease. Am J Cardiol 1995; 76: B12-6.
108. Manchanda SC, Krishnaswani S. Combination treatment with trimetazidine and diltiazem in stable angina pectoris. Heart 1997; 78: 353-7.
109. White HD, Lowe JB. Antianginal efficacy of perhexiline maleate in patients refractory to beta-adrenoreceptor blockade. Int J Cardiol 1983; 3: 145-55.
110. Cole PL, Beamer AD, McGowan N, Cantillon CO, Benfell K, Kelly RA, et al. Efficacy and safety of perhexiline maleate in refractory angina. A double-blind placebocontrolled clinical trial of a novel antianginal agent. Circulation 1990; 81: 1260-70.
111. Barry WH, Horowitz JD, Smith TW. Comparison of negative inotropic potency, reversibility, and effects on calcium influx of six calcium channel antagonists in cultured myocardial cells. Br J Pharmacol 1985; 85: 51-9.
112. Jeffrey FM, Alvarez L, Diczku V, Sherry AD, Malloy CR. Direct evidence that perhexiline modifies myocardial substrate utilization from fatty acids to lactate. J Cardiovasc Pharmacol 1995; 25: 469-72.
113. Roberts RK, Cohn D, Petroff V, Seneviratne B. Liver disease induced by perhexiline maleate. Med J Aust 1981; 2: 553-4.
114. Bouche P, Bousser MG, Peytour MA, Cathala HP. Perhexiline maleate and peripheral neuropathy. Neurology 1979; 29: 739-43.
115. Horowitz JD, Sia ST, Macdonald PS, Goble AJ, Louis WJ. Perhexiline maleate treatment for severe angina pectoriscorrelations with pharmacokinetics. Int J Cardiol 1986; 13: 219-29.
116. Lee L, Campbell R, Scheuermann-Freestone M, Taylor R, Gunaruwan P, Williams L, et al. Metabolic modulation with perhexiline in chronic heart failure: a randomized, controlled trial of short-term use of a novel treatment. Circulation 2005; 112: 3280-8.
117. Arslan F, de Kleijn DP, Timmers L, Doevendans PA, Pasterkamp G. Bridging innate immunity and myocardial ischemia/reperfusion injury: the search for therapeutic targets. Curr Pharm Des 2008; 14(12): 1205-16.
118. Connelly KA, Boyle AJ, Kelly DJ. Angiotensin II and the cardiac complications of diabetes mellitus. Curr Pharm Des 2007; 13(26): 2721-9.
119. Schaar JA, Mastik F, Regar E, den Uil CA, Gijsen FJ, Wentzel JJ, et al. Current diagnostic modalities for vulnerable plaque detection. Curr Pharm Des 2007; 13(10): 995-1001.